Literature DB >> 16859575

Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.

Kesava Reddy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16859575     DOI： 10.1016/s1558-7673(11)70151-3

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  4 in total

1.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

Authors:  Dan Huang; Yan Ding; Ming Zhou; Brian I Rini; David Petillo; Chao-Nan Qian; Richard Kahnoski; P Andrew Futreal; Kyle A Furge; Bin Tean Teh
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

Review 2.  Immunotherapy for metastatic renal cell carcinoma.

Authors:  Susanne Unverzagt; Ines Moldenhauer; Monika Nothacker; Dorothea Roßmeißl; Andreas V Hadjinicolaou; Frank Peinemann; Francesco Greco; Barbara Seliger
Journal:  Cochrane Database Syst Rev       Date:  2017-05-15

3.  Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.

Authors:  Wan-Xiang Zheng; Fei Yan; Qin Xue; Guo-Jun Wu; Wei-Jun Qin; Fu-Li Wang; Jun Qin; Chun-Juan Tian; Jian-Lin Yuan
Journal:  Onco Targets Ther       Date:  2015-08-10       Impact factor: 4.147

4.  Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.

Authors:  Maria Pinkerneil; Michèle J Hoffmann; Hella Kohlhof; Wolfgang A Schulz; Günter Niegisch
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.